Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $43 | $420 | $0 | $0 |
| % Growth | -89.8% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $32 | $43 |
| Gross Profit | $43 | $420 | -$32 | -$43 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $6,655 | $19,155 | $20,274 | $14,928 |
| G&A Expenses | $5,392 | $6,718 | $7,382 | $7,461 |
| SG&A Expenses | $5,392 | $6,718 | $7,382 | $7,461 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,047 | $25,873 | $27,656 | $22,389 |
| Operating Income | -$12,004 | -$25,453 | -$27,656 | -$22,938 |
| % Margin | -27,916.3% | -6,060.2% | – | – |
| Other Income/Exp. Net | $10 | -$98 | $1,741 | $204 |
| Pre-Tax Income | -$11,994 | -$25,551 | -$25,915 | -$22,185 |
| Tax Expense | -$782 | -$2,996 | -$4,717 | -$3,847 |
| Net Income | -$11,212 | -$22,555 | -$21,198 | -$18,887 |
| % Margin | -26,074.4% | -5,370.2% | – | – |
| EPS | -1.36 | -28.67 | -28.5 | -32.1 |
| % Growth | 95.3% | -0.6% | 11.2% | – |
| EPS Diluted | -1.36 | -28.67 | -28.5 | -32.1 |
| Weighted Avg Shares Out | 8,305 | 798 | 750 | 595 |
| Weighted Avg Shares Out Dil | 8,305 | 798 | 750 | 595 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $266 | $210 | $16 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $31 | $32 | $43 |
| EBITDA | -$11,998 | -$25,422 | -$27,624 | -$22,691 |
| % Margin | -27,902.3% | -6,052.9% | – | – |